Tag

Varenyam Healthcare

2 articles

Bharat Parenterals FY26 Transition Year, Innoxel Inflection

Bharat Parenterals reported FY26 as a transition year with consolidated revenue of ₹345.4 crore, flat YoY, but EBITDA surged 485% to ₹15.8 crore. Subsidiary Innoxel Lifesciences grew 174% to ₹72.4 cro

Bharat Parenterals FY26 Consolidated Loss ₹27.3 Cr

Bharat Parenterals reported consolidated FY26 revenue of ₹345.4 Cr with a PAT loss of ₹27.3 Cr, driven by subsidiary Innoxel's pre-commercial phase. Innoxel Lifesciences secured USFDA and EU-GMP appro